206 related articles for article (PubMed ID: 19466990)
1. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.
Hoffmann LS; Schmidt PM; Keim Y; Schaefer S; Schmidt HH; Stasch JP
Br J Pharmacol; 2009 Jul; 157(5):781-95. PubMed ID: 19466990
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells.
Hoffmann LS; Schmidt PM; Keim Y; Hoffmann C; Schmidt HH; Stasch JP
PLoS One; 2011; 6(8):e23596. PubMed ID: 21858179
[TBL] [Abstract][Full Text] [Related]
3. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
[TBL] [Abstract][Full Text] [Related]
5. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
6. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
7. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.
Zhou Z; Pyriochou A; Kotanidou A; Dalkas G; van Eickels M; Spyroulias G; Roussos C; Papapetropoulos A
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1763-71. PubMed ID: 18757489
[TBL] [Abstract][Full Text] [Related]
8. Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.
Jones AW; Durante W; Korthuis RJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):85-91. PubMed ID: 20605906
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase.
Schmidt P; Schramm M; Schröder H; Stasch JP
Eur J Pharmacol; 2003 May; 468(3):167-74. PubMed ID: 12754054
[TBL] [Abstract][Full Text] [Related]
11. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
Knorr A; Hirth-Dietrich C; Alonso-Alija C; Härter M; Hahn M; Keim Y; Wunder F; Stasch JP
Arzneimittelforschung; 2008; 58(2):71-80. PubMed ID: 18412020
[TBL] [Abstract][Full Text] [Related]
13. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Stasch JP; Schmidt P; Alonso-Alija C; Apeler H; Dembowsky K; Haerter M; Heil M; Minuth T; Perzborn E; Pleiss U; Schramm M; Schroeder W; Schröder H; Stahl E; Steinke W; Wunder F
Br J Pharmacol; 2002 Jul; 136(5):773-83. PubMed ID: 12086987
[TBL] [Abstract][Full Text] [Related]
14. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
Bawankule DU; Sathishkumar K; Sardar KK; Chanda D; Krishna AV; Prakash VR; Mishra SK
J Pharmacol Exp Ther; 2005 Jul; 314(1):207-13. PubMed ID: 15792996
[TBL] [Abstract][Full Text] [Related]
15. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
[TBL] [Abstract][Full Text] [Related]
17. Cobinamides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain.
Sharina I; Sobolevsky M; Doursout MF; Gryko D; Martin E
J Pharmacol Exp Ther; 2012 Mar; 340(3):723-32. PubMed ID: 22171090
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
19. NO- and haem-independent soluble guanylate cyclase activators.
Schmidt HH; Schmidt PM; Stasch JP
Handb Exp Pharmacol; 2009; (191):309-39. PubMed ID: 19089335
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.
Bellamy TC; Garthwaite J
Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
